192 related articles for article (PubMed ID: 36880594)
1. Thrombocytopenia during avacopan administration: A case report.
Morimoto N; Mori T; Shioji S; Watanabe H; Sakai K; Mori K; Yamamura A; Hanioka A; Akagi Y; Fujiki T; Mandai S; Mori Y; Ando F; Susa K; Iimori S; Naito S; Sohara E; Uchida S
Int J Rheum Dis; 2023 Aug; 26(8):1603-1607. PubMed ID: 36880594
[TBL] [Abstract][Full Text] [Related]
2. Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis.
Kataoka H; Tomita T; Nakanowatari M; Kondo M; Mukai M
Mod Rheumatol Case Rep; 2023 Jun; 7(2):444-447. PubMed ID: 36972244
[TBL] [Abstract][Full Text] [Related]
3. Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis.
Harigai M; Takada H
Mod Rheumatol; 2022 Apr; 32(3):475-483. PubMed ID: 34984461
[TBL] [Abstract][Full Text] [Related]
4. Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan.
Alvarez L; Kambham N; Su R
J Nephrol; 2023 Nov; 36(8):2365-2370. PubMed ID: 37036661
[TBL] [Abstract][Full Text] [Related]
5. Avacopan as an additional therapeutic intervention to promote renal recovery in severe ANCA-associated vasculitis: A case report.
Atrens AD; Hutton H; O'Sullivan E; Moore J; Madhan K
Nephrology (Carlton); 2024 Feb; 29(2):105-107. PubMed ID: 37985226
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study.
Harigai M; Kaname S; Tamura N; Dobashi H; Kubono S; Yoshida T
Mod Rheumatol; 2023 Mar; 33(2):338-345. PubMed ID: 35482532
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological and clinical profiles of avacopan (TAVNEOS
Maruyama Y; Yoshida T; Maruyama I
Nihon Yakurigaku Zasshi; 2023 Sep; 158(5):399-407. PubMed ID: 37460300
[TBL] [Abstract][Full Text] [Related]
8. CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum.
Turgeon D; Bakowsky V; Baldwin C; Cabral DA; Clements-Baker M; Clifford A; Cohen Tervaert JW; Dehghan N; Ennis D; Famorca L; Fifi-Mah A; Girard LP; Lefebvre F; Liang P; Makhzoum JP; Massicotte-Azarniouch D; Mendel A; Milman N; Reich HN; Robinson DB; Ross C; Rumsey DG; Soowamber M; Towheed TE; Trudeau J; Twilt M; Yacyshyn E; Yardimci GK; Khalidi N; Barra L; Pagnoux C
Rheumatology (Oxford); 2023 Aug; 62(8):2646-2651. PubMed ID: 36805625
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous manifestations of microscopic polyangiitis successfully controlled with avacopan alone.
Kamiya S; Koizumi H; Suzuki Y; Imai S; Yamashita Y; Ogawa-Momohara M; Takeichi T; Muro Y; Yasuda K; Akiyama M
J Dermatol; 2023 Jul; 50(7):e206-e207. PubMed ID: 36651057
[No Abstract] [Full Text] [Related]
10. Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report.
Furuto Y; Kawamura M; Yamashita J; Yoshikawa T; Namikawa A; Isshiki R; Takahashi H; Shibuya Y
BMC Nephrol; 2021 Jun; 22(1):220. PubMed ID: 34126959
[TBL] [Abstract][Full Text] [Related]
11. Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
Nguyen ID; Sinnathamby ES; Mason J; Urban B; Neuchat EE; Wenger DM; Ahmadzadeh S; Shekoohi S; Kaye AD
Clin Drug Investig; 2023 Aug; 43(8):595-603. PubMed ID: 37596445
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis.
Endo Y; Koga T; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kawakami A
Intern Med; 2018 Aug; 57(15):2247-2250. PubMed ID: 29526948
[TBL] [Abstract][Full Text] [Related]
13. [Update on treatment of ANCA-associated vasculitis: Granulomatosis with polyangiitis and Microscopic Polyangiitis].
Holle JU; Hellmich B; Moosig F
Z Rheumatol; 2022 May; 81(4):280-285. PubMed ID: 35061059
[TBL] [Abstract][Full Text] [Related]
14. Avacopan: First Approval.
Lee A
Drugs; 2022 Jan; 82(1):79-85. PubMed ID: 34826105
[TBL] [Abstract][Full Text] [Related]
15. How the Availability of Anti-C5a Agents Could Change the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Roccatello D; Fenoglio R; Oddone V; Sciascia S
Kidney Blood Press Res; 2022; 47(8):506-513. PubMed ID: 35665698
[TBL] [Abstract][Full Text] [Related]
16. A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain.
Macía M; Díaz-Encarnación M; Solans-Laqué R; Mallol EP; Castells AG; Escribano C; de Arellano AR
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):227-235. PubMed ID: 38126738
[TBL] [Abstract][Full Text] [Related]
17. Development of eosinophilic granulomatosis with polyangiitis during the clinical course of microscopic polyangiitis: A case report.
Ide H; Shimizu T; Koike Y; Abe K; Shigematsu K; Nishihata S; Kojima K; Ichinose K; Kawakami A
Medicine (Baltimore); 2022 Nov; 101(44):e31401. PubMed ID: 36343053
[TBL] [Abstract][Full Text] [Related]
18. AVACOPAN: A New Adjunctive Therapy for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Garg J; Frishman WH
Cardiol Rev; 2023 Jan-Feb 01; 31(1):3-6. PubMed ID: 36469359
[TBL] [Abstract][Full Text] [Related]
19. Treatment Approaches to Granulomatosis with Polyangiitis and Microscopic Polyangiitis.
Berti A; Cornec D; Dua AB
Rheum Dis Clin North Am; 2023 Aug; 49(3):545-561. PubMed ID: 37331732
[TBL] [Abstract][Full Text] [Related]
20. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
Jayne DRW; Bruchfeld AN; Harper L; Schaier M; Venning MC; Hamilton P; Burst V; Grundmann F; Jadoul M; Szombati I; Tesař V; Segelmark M; Potarca A; Schall TJ; Bekker P;
J Am Soc Nephrol; 2017 Sep; 28(9):2756-2767. PubMed ID: 28400446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
